Developing successful therapeutic antibodies can be hindered by poor developability properties such as expression, solubility, immunogenicity, stability, and polyspecificity. AlivaMab Discovery Services focuses on strategies that enhance developability profiles by leveraging transgenic technologies to minimize risks, deep screening methods for lead diversity, and comprehensive assessment packages.
The process of developability assessment involves a series of in silico and in vitro analyses at appropriate stages to characterize and select lead drug candidates based on specificity, stability, expression, and manufacturability. This approach aims to de-risk the transition from antibody discovery to development by identifying and addressing potential issues early on in the process.
Tools and techniques employed by AlivaMab Discovery Services for developability assessments include stability and aggregation characterization using Unchained Labs’ Uncle. These assessments play a crucial role in evaluating the quality and feasibility of antibody candidates, paving the way for more successful development and eventual commercialization.
Key considerations for evaluating the developability of an antibody encompass factors such as expression levels, solubility, immunogenicity, stability, and specificity. Understanding and optimizing these properties early in the development process can significantly impact the success rate of antibody drug candidates.
Current tools and techniques used in developability assessments range from in silico modeling to in vitro experiments that evaluate various aspects of antibody behavior. By combining different analytical approaches, researchers can gain a comprehensive understanding of the developability profile of a candidate antibody.
Stability and aggregation characterization are critical steps in the workflow of antibody assessment, as they provide insights into the long-term viability and efficacy of the drug candidate. By predicting and addressing potential stability issues, developers can enhance the chances of moving promising candidates forward in the development pipeline.
In conclusion, utilizing thorough developability assessments early in the development process can significantly improve the success rate of antibody drug candidates. By identifying and addressing potential issues related to expression, solubility, stability, and specificity, researchers can de-risk the transition from discovery to development, ultimately increasing the likelihood of bringing effective therapies to market.
- Developability assessments are crucial for enhancing the success rate of antibody drug candidates
- Tools such as stability and aggregation characterization play a key role in evaluating antibody quality
- Early optimization of developability properties can de-risk the transition from discovery to development
- Comprehensive understanding of an antibody’s developability profile is essential for successful commercialization
Tags: formulation
Read more on nature.com